Drug Trial Radar · NCT03568422
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
37
Actual
Start
Feb 5, 2019
Primary completion
Nov 21, 2022
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- Stand Up To Cancer; Canadian Breast Cancer Foundation; Ontario Institute for Cancer Research
- First posted
- Jun 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of disease and relieve some symptoms of cancer. One of the standard types of chemotherapy is a drug called paclitaxel (Taxol) given in a low dose every week for three out of four weeks. CFI-402257 is a new type of drug for breast cancer. Laboratory tests show that it may help slow the growth of breast cancer. This drug has been shown to shrink tumours in animals. CFI-402257 has been studied in a few people and appears well tolerated with little side effects. CFI-402257 seems promising but it is not clear if it can offer better results when given with paclitaxel compared to paclitaxel alone.
Conditions
- Breast Cancer
Interventions
CFI-402257Drug
Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 \& 16
PaclitaxelDrug
80 mg/m2 IV days 1, 8 \& 15 every 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Recommended Phase II Dose for CFI-402257Time frame: During cycle 1 (28 days)
- Phase II: Overall Response Rate Using RECIST 1.1Time frame: 2 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Kingston Health Sciences Centre
Kingston, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.